FEC100-taxotere | FEC100-taxotere-herceptin | |||
---|---|---|---|---|
N = 118 | %a | N = 46 | %a | |
Tumor type | ||||
Ductal carcinoma | 106 | 89.9 | 44 | 95.6 |
Lobular carcinoma | 7 | 5.9 | 1 | 2.2 |
Other | 5 | 4.2 | 1 | 2.2 |
Tumor size | ||||
T0-T1 | 5 | 4.3 | 1 | 2.3 |
T2 | 60 | 51.7 | 21 | 48.8 |
T3 | 24 | 20.7 | 11 | 25.6 |
T4 | 27 | 23.3 | 10 | 23.3 |
NA | 2 | 1.7 | 3 | 6.5 |
Histoprognostic grade | ||||
SBRI | 7 | 6.7 | 1 | 2.5 |
SBRII | 54 | 51.9 | 19 | 47.5 |
SBRIII | 43 | 41.3 | 20 | 50 |
NA | 14 | 11.9 | 6 | 13.1 |
Nodal status | ||||
Positive | 63 | 54.3 | 30 | 65.2 |
Negative | 53 | 45.7 | 16 | 34.8 |
NA | 2 | 1.7 | 0 | 0 |
Hormone receptor status | ||||
Positiveb | 77 | 66.3 | 23 | 50.0 |
Negativec | 39 | 33.6 | 23 | 50.0 |
NA | 2 | 1.7 | 0 | 0.0 |
HER-2 status | ||||
Positived | 5 | 4.7 | 46 | 100.0 |
Negative | 102 | 95.3 | 0 | 0.0 |
NA | 11 | 9.3 | 0 | 0.0 |
Clinical response | ||||
CR | 11 | 12.2 | 7 | 21.9 |
PR | 62 | 68.9 | 23 | 71.9 |
SD | 15 | 16.7 | 2 | 6.3 |
PD | 2 | 2.2 | 0 | 0.0 |
NA | 28 | 23.7 | 14 | 30.4 |
pCR | ||||
Yes | 25 | 21.2 | 18 | 40.0 |
No | 93 | 78.8 | 27 | 60.0 |
NA | 0 | 0.0 | 1 | 2.2 |